Analyst Ratings For Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
Today, Wedbush raised its price target on Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to $33.00 per share.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) is Buy with a consensus target price of $35.3333 per share, a potential 41.53% upside.
Some recent analyst ratings include
- 6/18/2018-Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has coverage initiated with a Overweight rating and $29.00 price target
- 6/18/2018-Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has coverage initiated with a Neutral rating
About Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Recent Trading Activity for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
Shares of Kiniksa Pharmaceuticals Ltd closed the previous trading session at 24,96 +0,59 2,40 % with 24.2 shares trading hands.
